Search Results - linzhao+cheng

5 Results

Sort By:

Induced Pluripotent Stem Cell Lines (BC1 and C7) and Plasmids (pEB-C5, pEB-Tg)

The Material consists of two induced pluripotent stem (iPS) cell lines derived from human bone marrow and cord blood.and plasmids used to create these virus-free and integration-free human iPS cell lines.

Published: 3/13/2025 | Inventor(s): Linzhao Cheng

Keywords(s): Basic Research Biomarker, Cell Model, Cloning Reagents, Discovery/Research Tools, In Vitro Research Tool, Plasmid, Research Reagent, Stem Cells

Category(s): Technology Classifications > Research Tools > Cell Lines, Technology Classifications > Research Tools > Stem Cells, Technology Classifications > Research Tools > Vectors & Plasmids, Technology Classifications > Research Tools

Engineered Anucleate Cellular and Extracellular Vesicles as a Novel Biologics Delivery Platform

UNMET NEED Biologic therapeutics, specifically antibodies, have demonstrated tremendous potential for treatment of a wide range of cancer types. Antibodies are designed to possess a strong affinity for a particular target, a very desirable characteristic for a drug. However, antibodies must be administered multiple times by injection, due to their...

Published: 3/13/2025 | Inventor(s): Linzhao Cheng, Hao Bai, Vasiliki Machairaki

Keywords(s): Drug Delivery Vehicle, Therapeutic Matter, Therapeutics, Vesicle

Category(s): Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities

Reprogramming Blood Cells from Healthy Donors and Patients to Pluripotent and Multipotent Stem Cells

C10865: Novel method to reprogram blood cells to pluripotent and multipotent stem cellsValue Proposition: JHU scientists have developed a method to reprogram human CB, adult bone marrow and peripheral blood cells from healthy donors without any pretreatment to pluripotent and multipotent stem cells. • This novel method uses easily accessible...

Published: 3/13/2025 | Inventor(s): Linzhao Cheng

Keywords(s): Cell Model, Discovery/Research Tools, Disease Indication, In Vitro Research Tool, Osteoporosis, Skeletal Disorders, Stem Cells, Translational Research Biomarker

Category(s): Technology Classifications > Research Tools > Cell Lines, Technology Classifications > Research Tools > Stem Cells, Technology Classifications > Research Tools, Clinical and Disease Specializations > Endocrinology

A p105-based NF-(kappa) B Super repressor

C04290: A p105-based NF-(kappa) B Super repressor Technical Details: Nuclear factor (NF)-kB is a family of transcription factors that regulate immune and inflammatory responses, programmed cell death (apoptosis), and developmental processes. In normal cells, NF-kB is latent, and is activated transiently by stimuli and stresses. However, under pathological...

Published: 3/13/2025 | Inventor(s): Li Lin

Keywords(s): Biologics, Cancers, Chemotherapy, Disease Indication, Nucleic Acid, Single, Skin Cancer, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Dermatology, Clinical and Disease Specializations > Oncology > Skin Cancer, Technology Classifications > Therapeutic Modalities > Gene Therapies, Technology Classifications > Therapeutic Modalities > Proteins, Technology Classifications > Therapeutic Modalities > Targets, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities

Modulation of systemic Immune Responses by Transplantation of Hemotopoietic Stem Cells Transduced with Genes Encoding Antigens and Antigen Presenting Cell Regulatory Molecules

C03855: Modulation of Systemic Immune Responses by Transplantation of Hemotopoietic Stem Cells Transduced with Genes Encoding Antigens and Antigen Presenting Cell Regulatory Molecules Technical Details: The initiation of T cell-dependent immune responses depends on presentation of antigens by bone marrow-derived antigen-presenting cells such as...

Published: 3/13/2025 | Inventor(s): Yan Cui, Katherine Whartenby, Linzhao Cheng, Curt Civin, Drew Pardoll

Keywords(s): Biologics, Cancers, Cell Therapy/Gene Therapy, Cell Therapy/Immunotherapy, Combination, Disease Indication, Nucleic Acid, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type, Whole cell

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Cell Therapies, Technology Classifications > Therapeutic Modalities > Gene Therapies, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities